Outcome in the Rights Issue

The subscription period in the Rights Issue ended on February 24, 2025. The final outcome shows that a total of 71,562,122 units have been subscribed for through the Rights Issue, corresponding to approximately 62.1 percent of the Rights Issue. 51,625,491 units were subscribed through use of unit rights, corresponding to approximately 44.8 percent of the Rights Issue. Furthermore, 11,240,979 units were subscribed for without use of unit rights, corresponding to approximately 9.8 percent of the Rights Issue and 8,695,652 units were subscribed by top-down underwriters, corresponding to approximately 7.5 percent of the Rights Issue. Each unit consists of fifty (50) newly issued shares. In total, 3,578,106,100 new shares in the Company were subscribed. Through the Rights Issue, the Company will receive approximately SEK 16.5 million before issue costs, of which SEK 4.5 million is paid through offset.

Allocation of units subscribed for without the support of unit rights

Allocation of units subscribed for without the support of unit rights has taken place in accordance with what is stated in the information document that the Company has prepared in connection with the Rights Issue, in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council, Annex IX, and which was published on January 10, 2025. Notification of such allocation is announced separately through settlement notes. Nominee-registered shareholders receive notification of allotment in accordance with instructions from the respective nominee.

Shares and share capital

Through the Rights Issue, the number of shares in the Company increase by 3,578,106,100 shares, from 5,759,303,014 shares to 9,337,409,114 shares and the share capital increase by approximately SEK 16,459,288.06, from approximately SEK 26,492,793.86 to approximately SEK 42,952,081.92.

Trading with paid subscribed units ("BTU")

Trading with BTU takes place on Spotlight Stock Market until the conversion of BTU into shares after the Rights Issue has been registered with the Swedish Companies Registration Office. Registration with the Swedish Companies Registration Office is expected to take place during week 12, 2025.

Compensation to underwriters

In connection with the Rights Issue, investors have entered underwriting commitments. For bottom underwriting commitments made, an underwriting compensation of fifteen (15) percent of the underwritten amount is paid in cash or alternatively twenty (20) percent of the underwritten amount in the form of units. For top down-underwriting commitments made, an underwriting compensation of twenty (20) percent of the underwritten amount in the form of units. Underwriters who wish to receive underwriting compensation in the form of units must notify Mangold Fondkommission AB no later than March 7, 2025. The subscription price for any units issued as underwriting compensation has been set at SEK 0.23 per unit, corresponding to SEK 0.0046 per share, which corresponds to the subscription price in the Rights Issue. In total, a maximum of 5,690,597 units may be issued as underwriting compensation to the underwriters.

Advisers

Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the Rights Issue.

This disclosure contains information that PEPTONIC medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on February 28, 2025 08:00 CET.

For more information contact:

Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07

About PEPTONIC medical AB

PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates a subsidiary, Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release contains certain forward-looking information that reflects the Company's present view of future events as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development, and actual outcomes may differ materially from the statements set forth in the forward-looking information.